Du är här

2014-05-01

InvestmentPitch: Zacks Small-Cap Research Updates Coverage on OxySure Systems (OTCQB:OXYS) - Video Research Alert on InvestmentPitch.com

Vancouver, BC, May 1, 2014 - Zacks Small-Cap Research has updated coverage on
OxySure Systems (OTCQB:OXYS). Following the release of the 4th quarter and
full year results for the period ending December 31, 2013, analyst Jason
Napodano has reiterated his target price of $1.50, a premium of 142% to the
$0.62 price on April 16th, the day the report was issued.

InvestmentPitch.com has produced a "video research alert" about OxySure based
on this report. If this link is not enabled, please
visitwww.InvestmentPitch.comand enter "OxySure" in the search box.

Revenues in the 4th quarter totaled $540,000, up 612% from the same period in
2012. Revenues far exceed expectations, as the anticipated dramatic slowdown
in military orders during the fourth quarter of 2013 thanks to the government
shutdown and sequester that occurred in November 2013, had little if any
effect on revenues.

According to the Zacks' report, OxySure is doing some really neat stuff with
the military, including working with the Navy on an emergency escape
breathing device and with the SEAL team on providing oxygen for high-altitude
jumps.

Analyst Jason Napodano stated, "OxySure is branching out beyond just first-aid
devices like the Model 615, and
we do not think investors have come to grips with the potential for smaller,
more compact devices for battlefield use being developed right now by the
company
."

For those of you that are new to the OxySure story, the company has pioneered
a safe and easy to use solution to produce medically pure oxygen from inert
powders, eliminating the need for a pressurized gas tank.

The company's Model 615 has FDA 510k clearance for over the counter sale,
giving the company a clear advantage over oxygen systems reliant on
pressurized oxygen tanks, which require a prescription. Users simply plug in
the mask, turn the knob, and place the mask over the nose and mouth. The
Model 615 has quickly gained adoption amongst various school districts,
military units, and institutional buyers, where early administration of
medical oxygen in respiratory emergencies can often save a trip to the
hospital. The Model 615 recently received CE Mark approval, a critical step
toward launching this unique product into the 30 countries belonging to the
European Economic Area.

Napodano further commented, "With an improved liquidity and less debt, we
believe OxySure now has enough
cash to fund operations into the third quarter 2014. By that time, we believe
the company could be posting break-even operations
."

The report further states that for 2015, OxySure could post revenues of $5
million.

The company currently trades at $0.78, and with 26 million shares outstanding,
the company is capitalized at $20.3 million.

For more information about OxySure, please visit the company's
websitewww.oxysure.com. Investor relations is handled by Stonegate
Securities, which can be reached at 214-987-4121 or by email
atinvestors@oxysure.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution
for creating and hosting financial video content, and distributing it across
multiple platforms to investors and financial professionals, specializes in
producing corporate interviews and three minute videos based on news releases
and research reports. Please visit InvestmentPitch.com and browse our
extensive library of investment videos.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan@investmentpitch.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InvestmentPitch via Globenewswire

HUG#1782106

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.